DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, Volume 2Vincent T. DeVita, Theodore S. Lawrence, Steven A. Rosenberg Acclaimed by the worldwide medical community as "a staple reference text in the medical oncologist's library" (JAMA), DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology is now in its Eighth Edition. This edition is in full color for the first time, has a new editor, Theodore S. Lawrence, MD, PhD, a radiation oncologist, and has two Associate Scientific Advisors, Ronald A. DePinho, MD and Robert A. Weinberg, PhD, with special expertise in molecular biology. More than 40 chapters are entirely new, and more than 70 have been rewritten by new contributing authors. Plus, this edition has an exciting new companion Website. The text provides cutting-edge, practical information on the science of oncology and the multimodality treatment of every cancer type. To ensure a balanced, multidisciplinary approach, each major treatment chapter is co-authored by a surgeon, a medical oncologist, and a radiation oncologist. Treatment of each cancer type is discussed by stage, with coordinated guidelines on the role of each treatment modality at each stage. Each major treatment section is preceded by an updated brief chapter describing the molecular biology of the cancer and the implications of molecular biology for patient management. Full consideration is also given to cancer prevention, screening, palliative care, supportive oncology, and quality of life issues. A companion Website offers the fully searchable online text, an image bank, links to journal articles, and a question bank. |
Contents
VOLUME | 1487 |
Principles of Immunotherapy 351 | 1491 |
Cancer Screening 659 | 1496 |
Background Replication Cycle and Molecular Genetics 169 | 1497 |
Staging 1134 | 1501 |
Contents | 1512 |
Potential Clinical Applications of Molecular Advances 1230 | 1518 |
Carcinoma of the Vagina | 1521 |
Treatment of Metastatic Cancer | 2461 |
Metastatic Cancer to the Lung | 2476 |
Musculoskeletal Cancer 721 | 2482 |
Clinical Trials 571 | 2485 |
Results | 2487 |
Gynecologic Cancers 670 | 2490 |
Anatomy 1285 | 2493 |
Metastatic Cancer to the Bone | 2510 |
Carcinoma of the Vulva | 1528 |
Epothilones 455 | 1535 |
Cancer of the Uterine Body | 1543 |
Chemoprevention 609 | 1545 |
Uterine Sarcomas | 1557 |
Gestational Trophoblastic Diseases | 1564 |
Colon Cancer 1232 | 1574 |
Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors 463 | 1584 |
Monoclonal Antibodies 537 | 1586 |
Cancer of the Breast | 1595 |
Her Family 469 | 1601 |
Epidemiology 1232 | 1604 |
Malignant Tumors of the Breast | 1606 |
Diagnosis and Biopsy | 1612 |
Local Management of Invasive Cancer | 1620 |
Prognostic and Predictive Factors | 1632 |
Integration of Multimodality Primary Therapy | 1640 |
Screening Populations at High Risk of Hepatocellular Carcinoma 1139 | 1644 |
Introduction 351 | 1652 |
Cancer of the Endocrine System | 1655 |
Thyroid Tumors | 1663 |
Special Considerations 1311 | 1668 |
Parathyroid Cancer | 1682 |
Adrenal Tumors | 1690 |
Pheochromocytomas | 1697 |
Genetic and Environmental Risk Factors 1233 | 1700 |
Tumor Classification Histopathology and Molecular Genetics | 1703 |
Cholangiocarcinomas 1157 | 1712 |
Natural History and Patterns of Failure 1000 | 1713 |
Emerging Therapeutic Options | 1718 |
Incidence 1186 | 1720 |
Clinical Presentation 1001 | 1723 |
Anatomy of the Colon 1236 | 1724 |
Treatment of the Carcinoid Tumor | 1731 |
Alkylating Agents 407 | 1733 |
Screening 1238 | 1736 |
Familial Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Types 2A and 2B | 1738 |
Gastrointestinal Stromal Tumors 1204 | 1741 |
TNFRelated ApoptosisInducing Ligand 474 | 1750 |
Immunoglobulin Structure 538 | 1771 |
Sarcomas of Bone | 1794 |
Biopsy Technique and Timing | 1801 |
Chemotherapy for Bone Sarcomas | 1807 |
Background 549 | 1823 |
Benign and Malignant Mesothelioma | 1835 |
Solitary Fibrous Tumors of Pleura | 1841 |
Malignant Peritoneal Mesothelioma | 1856 |
Infectious Agents and Cancer 549 | 1860 |
Cancer of the Skin | 1863 |
Melanoma | 1889 |
Integrins 475 | 1893 |
Cutaneous Melanoma | 1897 |
Diagnosis of Primary Melanoma | 1903 |
Diagnostic Studies and Pretreatment Staging 1001 | 1908 |
General Considerations in Clinical Management of a Newly Diagnosed | 1909 |
Conclusions 475 | 1912 |
Management of Clinically Localized Melanoma | 1916 |
Principles of Isolation Perfusion 701 | 1923 |
Intraocular Melanomas | 1951 |
Invasion and Metastasis 117 | 1952 |
Metastatic WorkUp | 1957 |
Posttreatment Quality of Life | 1963 |
Percutaneous Hepatic Perfusion 707 | 1964 |
Cancer Stem Cells 135 | 1974 |
Neoplasms of the Central Nervous System | 1975 |
Histopathologic Features and Histogenesis 1204 | 1978 |
Neurodiagnostic Tests | 1981 |
Specific Central Nervous System Neoplasms | 1988 |
Gliomatosis Cerebri | 1996 |
Treatment 1003 | 2027 |
Historical Perspectives | 2031 |
Cancers of Childhood | 2033 |
Solid Tumors of Childhood | 2043 |
Wilms Tumor | 2050 |
Osteosarcoma and Ewings Sarcoma | 2057 |
Rhabdomyosarcoma | 2067 |
Germ Cell Tumors | 2074 |
Lymphomas | 2085 |
Chemistry 407 | 2088 |
NonHodgkins Lymphomas | 2098 |
Helicobacter Pylori 554 | 2100 |
Principles of the World Health Organization Classification of Lymphoid Neoplasms | 2106 |
Specific Disease Entities | 2114 |
Special Clinical Situations | 2136 |
Virus 175 | 2139 |
Cutaneous TCell Lymphomas | 2143 |
Staging and Prognosis 1239 | 2147 |
Principles of Therapy of Mycosis Fungoides and the Sézary Syndrome | 2149 |
Pharmacology of Cancer Biotherapeutics | 2152 |
Autologous and Allogeneic Bone Marrow Transplantation | 2155 |
Design and Analysis of Clinical Trials 571 | 2158 |
Management and Therapy | 2161 |
Hodgkin Lymphoma | 2167 |
Interferon Signaling Pathways 497 | 2170 |
Nodular Lymphocyte Predominance Hodgkin Lymphoma | 2174 |
CardiopulmonaryVascular System 710 | 2180 |
Acute Leukemias | 2221 |
Deletions and Numeric Abnormalities in Acute Leukemias | 2227 |
Acute Myelogenous Leukemia | 2233 |
Stem Cell Transplantation for Acute Myelogenous Leukemia | 2243 |
Acute Lymphoblastic Leukemia | 2255 |
Chronic Leukemias | 2267 |
Plasma Cell Neoplasms | 2305 |
Alkylating AgentSteroid Conjugates | 2311 |
Changes in DNA Methylation 478 | 2319 |
Treatment | 2324 |
Paraneoplastic Syndromes | 2343 |
Head and Neck Cancer Chemoprevention 616 | 2345 |
Obesity and Physical Activity | 2346 |
Cutaneous Manifestations of Cancer | 2349 |
Approach to the Patient with Paraneoplastic Neurologic Disease | 2359 |
Gastrointestinal Cancers 664 | 2376 |
HepaticoBiliary System 713 | 2381 |
Summary 668 | 2384 |
Diagnosis and Treatment of Peritoneal Carcinomatosis | 2389 |
DNA Viruses 177 | 2401 |
Acquired Immunodeficiency SyndromeAssociated Lymphomas | 2407 |
Hodgkins Lymphoma | 2413 |
Common Features of Platinum Chemistry 420 | 2415 |
Lymphomas | 2423 |
Increased Intracranial Pressure | 2435 |
Spinal Cord Compression | 2441 |
Hyperuricemia | 2448 |
Genitourinary 720 | 2455 |
Rectal Cancer 1285 | 2459 |
Small Cell Lung Cancer 946 | 2512 |
Controlling Side Effects of Treatment | 2516 |
Morbidity of Radiofrequency Thermal Ablation 728 | 2522 |
Malignant Effusions of the Pleura and Pericardium | 2523 |
Malignant Ascites | 2533 |
Stem Cell Transplantation | 2541 |
Considerations Related to Individual Tumor Types 729 | 2562 |
Infections in the Cancer Patient | 2569 |
Diagnosis and Management of Infectious Diseases Syndromes | 2579 |
Selected Pathogens of Interest in Oncology | 2601 |
Clinical Presentation and Pretreatment Evaluation 1048 | 2607 |
Determinants of Cellular Sensitivity and Resistance to Platinum Agents 423 | 2615 |
Management of Adverse Effects of Treatment | 2617 |
Total Mesorectal Resection 1290 | 2627 |
Cell Signaling | 2634 |
Nausea and Vomiting Syndromes | 2640 |
Diarrhea and Constipation | 2646 |
Conclusions | 2654 |
Categories of Tumor Antigens Can be Defined by Expression Patterns 352 | 2655 |
Direct Cytoprotectants | 2660 |
Influence of Immune System on Tumor Development 363 | 2663 |
Practice of Oncology | 2666 |
Pulmonary Toxicity | 2668 |
Cardiac Toxicity | 2678 |
Tobacco Dependence and Its Treatment 593 | 2685 |
Methotrexate 427 | 2686 |
Anatomy and Physiology | 2689 |
Effects of Cytotoxic Agents on Adult Women | 2695 |
Management of Unresectable Primary and Locally Advanced Disease T4 1296 | 2700 |
Prevention and Management of Erectile and Ejaculatory Dysfunction | 2706 |
Principles of Oncology | 2711 |
Evaluation of the Patient with CancerRelated Fatigue | 2712 |
Immunologic Effects of Interferon 499 | 2717 |
Second Cancers | 2718 |
Pharmacology of Cancer Chemotherapy 385 | 2722 |
Pancreatic Cancer 1086 | 2728 |
Colorectal Cancer Epidemiology and Pathobiology 1218 | 2730 |
Conclusion | 2739 |
Goals of Survivorship Health Care | 2745 |
Neurocognitive Effects | 2751 |
Anatomy 1301 | 2757 |
Nutrition Support | 2791 |
Hepadnaviruses and Hepatocellular Carcinoma 178 | 2793 |
Techniques of Providing Nutritional Support | 2797 |
Ethical and Legal Aspects of Nutrition Support | 2803 |
Prostate Cancer | 2810 |
Cancer of the Prostate 1392 | 2811 |
Assessing Sexual Function | 2814 |
Outcome | 2822 |
Characteristics of Pancreatic Exocrine Malignancies 1086 | 2825 |
Explanations | 2828 |
Care Without Chemotherapy | 2834 |
The Final Days | 2843 |
Rehabilitation of the Cancer Patient | 2857 |
VOLUME | 2868 |
S1 431 | 2882 |
Societal Issues in Oncology | 2885 |
EndofLife Care | 2895 |
Cancer Genetics | 2902 |
Developing and Selecting Quality Indicators and Measures | 2908 |
Regulatory Issues | 2914 |
Drug Safety Reporting and Evaluation | 2920 |
Race and Cancer | 2928 |
Information Systems in Oncology | 2935 |
Advantages | 2941 |
Complementary Alternative and Integrative Therapies | 2949 |
Specific Complementary and Alternative Medicine Therapies | 2955 |
Lung Cancer Chemoprevention 617 | 2962 |
Newer Approaches in Cancer Treatment | 2965 |
EpsteinBarr Virus 185 | 2968 |
Cancer Gene Therapy Applications | 2972 |
STEVEN A ROSENBERG | 2979 |
Focused Ultrasound | 2991 |
RNA Inhibition | 3001 |
Historical Perspective 283 | 3002 |
MiRNAs As Drugs | 3007 |
Charged Particle Therapy | 3013 |
Gleason Score 1394 | 3018 |
Robotic Surgery | 3021 |
Anesthesia for Oncologic Surgery 284 | 3025 |
Conclusions 623 | 3029 |
Nanotechnology | 3031 |
| 1 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 14 | |
| 16 | |
| 21 | |
| 26 | |
| 29 | |
| 32 | |
| 33 | |
| 35 | |
| 37 | |
| 38 | |
| 43 | |
| 45 | |
| 46 | |
| 49 | |
| 53 | |
| 57 | |
Kaposis SarcomaAssociated Herpesvirus 186 | 60 |
Typical Carcinoid and Atypical Carcinoid 963 | 62 |
799 | 63 |
Distinct Groups of Urothelial Tumors 1324 | 64 |
Screening for Lung Cancer 681 | 65 |
Ligands and Receptors | 67 |
Principles of Medical Oncology 337 | 68 |
Tumor Immune Surveillance 191 | 69 |
Histologic Types of Renal Carcinoma 1331 | 71 |
Formation of Multiprotein Signaling Complexes | 74 |
Asbestos 223 | 77 |
Cell Cycle | 80 |
Pharmacogenomics 402 | 84 |
Proteasome Inhibitors | 88 |
Support during Treatment and Rehabilitation of the Chemoradiation Patient 878 | 92 |
Hereditary Diffuse Gastric Cancer 642 | 93 |
Introduction 527 | 94 |
Small Cell Cancers 1311 | 97 |
Taxanes | 102 |
Cancers of the Bladder Renal Pelvis and Ureter 1358 | 105 |
New Taxane Formulations 451 | 109 |
Other editions - View all
Common terms and phrases
adjuvant chemotherapy adrenal associated benign biopsy bone brachytherapy BRCA1 BRCA2 breast cancer Cancer Center carcinoid tumors cell carcinoma cell tumors cervical cancer chromosome cisplatin Clin Oncol clinical diagnosis dose doxorubicin endocrine endometrial cancer epithelial evaluation excision follow-up gene genetic grade growth Gynecol Oncol Gynecologic Oncology Group histologic hormone hysterectomy ifosfamide incidence Int J Radiat invasive involvement irradiation lesions lymph node malignant mesothelioma margins median melanoma mesothelioma metastases metastatic disease mg/m² molecular mutations neoadjuvant neoplasia neoplasms Oncol Biol Phys osteosarcoma outcome ovarian cancer overall survival paclitaxel pancreatic papillary parathyroid carcinoma pathologic patients treated pelvic phase pleural postoperative preoperative prognostic factors Radiat Oncol Biol radiation therapy radiotherapy randomized trial receptor recurrence regimen reported resection response rate risk soft tissue sarcoma subtypes Surg surgery surgical survival rates syndrome tamoxifen thyroid cancer thyroid carcinoma tients tion trastuzumab treatment uterine vaginal vulvar women